Ventyx Biosciences (VTYX) Stock Forecast, Price Target & Predictions
VTYX Stock Forecast
Ventyx Biosciences stock forecast is as follows: an average price target of $33.86 (represents a 1378.60% upside from VTYX’s last price of $2.29) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
VTYX Price Target
The average price target for Ventyx Biosciences (VTYX) is $33.86 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $60.00 to $6.00. This represents a potential 1378.60% upside from VTYX's last price of $2.29.
VTYX Analyst Ratings
According to 8 Wall Street analysts, Ventyx Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for VTYX stock is 0 'Strong Buy' (0.00%), 7 'Buy' (87.50%), 1 'Hold' (12.50%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Ventyx Biosciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 13, 2024 | Emily Bodnar | H.C. Wainwright | $6.00 | $2.98 | 101.34% | 162.01% |
| Jun 06, 2024 | Jeff Jones | Oppenheimer | $10.00 | $5.28 | 89.39% | 336.68% |
| Mar 12, 2024 | Derek Archila | Wells Fargo | $16.00 | $8.42 | 90.02% | 598.69% |
| Mar 12, 2024 | Jeff Jones | Oppenheimer | $12.00 | $8.42 | 42.52% | 424.02% |
| Dec 19, 2022 | - | Goldman Sachs | $50.00 | $32.64 | 53.19% | 2083.41% |
| Nov 17, 2022 | Matthew Harrison | Morgan Stanley | $45.00 | $25.43 | 76.96% | 1865.07% |
| Sep 13, 2022 | Michael Yee | Jefferies | $60.00 | $38.11 | 57.44% | 2520.09% |
| May 12, 2022 | Yasmeen Rahimi | Piper Sandler | $50.00 | $14.53 | 244.12% | 2083.41% |
The latest Ventyx Biosciences stock forecast, released on Jun 13, 2024 by Emily Bodnar from H.C. Wainwright, set a price target of $6.00, which represents a 101.34% increase from the stock price at the time of the forecast ($2.98), and a 162.01% increase from VTYX last price ($2.29).
Ventyx Biosciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 4 |
| Avg Price Target | - | - | $11.00 |
| Last Closing Price | $2.29 | $2.29 | $2.29 |
| Upside/Downside | -100.00% | -100.00% | 380.35% |
In the current month, the average price target of Ventyx Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Ventyx Biosciences's last price of $2.29. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jun 13, 2024 | H.C. Wainwright | Neutral | Neutral | Hold |
| Jun 06, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 06, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Mar 12, 2024 | Wells Fargo | - | Overweight | Upgrade |
| Dec 19, 2022 | Goldman Sachs | - | Buy | Initialise |
| Sep 13, 2022 | Needham | Buy | Buy | Hold |
| Sep 12, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 12, 2022 | Credit Suisse | Outperform | Outperform | Hold |
| Sep 12, 2022 | Jefferies | Buy | Buy | Hold |
| May 12, 2022 | Piper Sandler | Overweight | Overweight | Hold |
Ventyx Biosciences's last stock rating was published by H.C. Wainwright on Jun 13, 2024. The company gave VTYX a "Neutral" rating, the same as its previous rate.
Ventyx Biosciences Financial Forecast
Ventyx Biosciences Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Ventyx Biosciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. VTYX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Ventyx Biosciences EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict VTYX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Ventyx Biosciences's previous annual EBITDA (undefined) of $NaN.
Ventyx Biosciences Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-33.87M | $-34.34M | $-35.04M | $-35.75M | $-41.01M | $-36.51M | $-40.83M |
| High Forecast | $-33.87M | $-34.34M | $-35.04M | $-35.75M | $-41.01M | $-32.71M | $-40.83M |
| Low Forecast | $-33.87M | $-34.34M | $-35.04M | $-35.75M | $-41.01M | $-39.56M | $-40.83M |
| Surprise % | - | - | - | - | - | - | - |
Ventyx Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VTYX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Ventyx Biosciences SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Ventyx Biosciences's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to VTYX last annual SG&A of $NaN (undefined).
Ventyx Biosciences EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.48 | $-0.49 | $-0.50 | $-0.51 | $-0.58 | $-0.52 | $-0.58 |
| High Forecast | $-0.48 | $-0.49 | $-0.50 | $-0.51 | $-0.58 | $-0.46 | $-0.58 |
| Low Forecast | $-0.48 | $-0.49 | $-0.50 | $-0.51 | $-0.58 | $-0.56 | $-0.58 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Ventyx Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VTYX previous annual EPS of $NaN (undefined).
Ventyx Biosciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.29 | $33.86 | 1378.60% | Buy |
| IMCR | Immunocore | $33.55 | $75.50 | 125.04% | Buy |
| REPL | Replimune Group | $11.13 | $24.20 | 117.43% | Buy |
| GPCR | Structure Therapeutics | $40.84 | $86.00 | 110.58% | Buy |
| SNDX | Syndax Pharmaceuticals | $19.12 | $36.00 | 88.28% | Buy |
| TVTX | Travere Therapeutics | $13.48 | $21.60 | 60.24% | Buy |
| ASND | Ascendis Pharma | $119.22 | $174.46 | 46.33% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| IDYA | IDEAYA Biosciences | $37.46 | $46.13 | 23.14% | Buy |
| NUVL | Nuvalent | $87.45 | $107.33 | 22.73% | Buy |
| VRNA | Verona Pharma | $29.78 | $33.00 | 10.81% | Buy |
| PCVX | Vaxcyte | $116.00 | $124.14 | 7.02% | Buy |
| PTGX | Protagonist Therapeutics | $47.02 | $50.00 | 6.34% | Buy |
| UTHR | United Therapeutics | $339.12 | $312.50 | -7.85% | Buy |
| ACLX | Arcellx | $76.89 | $61.00 | -20.67% | Buy |
| CERE | Cerevel Therapeutics | $44.96 | $33.50 | -25.49% | Buy |
VTYX Forecast FAQ
Is Ventyx Biosciences a good buy?
Yes, according to 8 Wall Street analysts, Ventyx Biosciences (VTYX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 87.50% of VTYX's total ratings.
What is VTYX's price target?
Ventyx Biosciences (VTYX) average price target is $33.86 with a range of $6 to $60, implying a 1378.60% from its last price of $2.29. The data is based on 8 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Ventyx Biosciences stock go up soon?
According to Wall Street analysts' prediction for VTYX stock, the company can go up by 1378.60% (from the last price of $2.29 to the average price target of $33.86), up by 2520.09% based on the highest stock price target, and up by 162.01% based on the lowest stock price target.
Can Ventyx Biosciences stock reach $3?
VTYX's average twelve months analyst stock price target of $33.86 supports the claim that Ventyx Biosciences can reach $3 in the near future.
What are Ventyx Biosciences's analysts' financial forecasts?
Ventyx Biosciences's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-118M (high $-115M, low $-121M), average SG&A $0 (high $0, low $0), and average EPS is $-1.677 (high $-1.624, low $-1.721). VTYX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-139M (high $-139M, low $-139M), average SG&A $0 (high $0, low $0), and average EPS is $-1.97 (high $-1.97, low $-1.97).